S
Sacituzumab Govitecan
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Sacituzumab Govitecan
General information
Subsidy Information and Financing Scheme
[MSHL] Sacituzumab govitecan Powder For Solution For Infusion 180 mg
Treatment of unresectable locally advanced or metastatic triple negative breast cancer in patients who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Treatment of patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Drug Guidance for Subsidy
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended sacituzumab govitecan for inclusion on the MOH List of Subsidised Drugs for treating patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The decision was based on the unfavourable cost effectiveness of sacituzumab govitecan compared with chemotherapy, and the unacceptable price-volume agreement proposed by the company.
Clinical indication, subsidy class and MediShield Life claim limit for sacituzumab govitecan are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Trodelvy Powder For Solution For Infusion 180 mg |
|